No clear relationship between antihypertensive class and cognitive function over 12 months in a cohort study of community-dwelling adults aged 80 and over

Ruth Peters, Ruth Peters

Abstract

Background: Hypertension is prevalent in older adults. Hypertension has also been associated with an increased risk of cognitive decline. However, evidence relating to the impact of antihypertensive use is mixed. Calcium-channel blockers (CCB) have been suggested as the most beneficial class of antihypertensive for protection of cognition in older adults, however, to date, there have been no cohort studies designed to examine this.

Methods: Community-dwelling treated hypertensive adults aged 80 and over were recruited from general practice sites and followed for 1 year. Cognitive function was assessed at baseline and 12 months using the modified Mini-Mental State Exam (3MS). Regression was used to examine the association between 12-month exposure to antihypertensive class and change in cognitive function.

Results: A total of 292 participants completed the study. Mean change in 3MS score was a rise of 0.53 [standard deviation (SD) 4.7] 3MS points in those taking CCBs (n = 135) compared with a drop of 0.09 (SD 5.1) in those without (n = 157) p = 0.28. There was no relationship between CCBs or between any antihypertensive class and change in cognitive function over 1 year. Additional analyses using a clinically meaningful fall of 5 or more 3MS points showed similar results.

Conclusion: In a hypertensive community-dwelling older adult population treated with antihypertensives, there was no evidence that CCBs were protective of cognitive function over a 12-month exposure. If a protective effect is present, it may be small or require a longer treatment period. Larger longer studies are required for confirmation.

Keywords: aged 80 and over; anticholinergic; antihypertensives; cognitive function.

Conflict of interest statement

Conflict of interest statement: The author declares that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Flow chart of study participants.

References

    1. Skoog I, Lernfelt B, Landahl S, et al. 15 year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–1145.
    1. Health Survey for England. 2009 trend tables. UK: Health and Social Care Information Centre, (2010; accessed 4 June 2016).
    1. United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Ageing 2017 (ST/ESA/SER.A/408). (accessed 18 Dec 2018)
    1. Gelber R, Ross G, Petrovitch H, et al. Antihypertensive medication use and risk of cognitive impairment. The Honolulu-Asia aging study. Neurol 2013; 81: 1–8.
    1. Prince M, Wimo A, Guerchet M, et al. World Alzheimer report 2015, the global impact of dementia. London: Alzheimer’s Disease International, 2015.
    1. Forette F Seux M Staessen J et al. .;. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment. Arch Int Med 2002; 162: 2046–2052.
    1. Forette F, Seux M, Staessen J, et al. Prevention of dementia in a randomised double blind placebo controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351.
    1. Paris D, Bachmeier C, Patel N, et al. Selective antihypertensive dihydropyridines lower Aß accumulation by targeting both the production and the clearance of Aß across the blood-brain barrier. Molecul Med 2011; 17:149–162.
    1. Lovell MA, Abner E, Kryscio R, et al. Calcium channel blockers, progression to dementia, and effects on amyloid beta peptide production. Oxid Med Cell Longev 2015; 2015: 787805.
    1. Ros Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009; 27: 1107–1114.
    1. Maxwell C, Hogan D, Ebly E. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian study of health and aging. CMAJ 1999; 161: 501–506.
    1. Trompet S, Westendorp R, Kamper A, et al. Use of calcium antagonists and cognitive decline in old age The Leiden 85-plus study. Neurobiol Aging 2008; 29: 306–308.
    1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–2158.
    1. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatr 1987; 48: 314–318.
    1. Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr 2008; 8: 24.
    1. Peters R Beckett N Forette F et al. .;. HYVET Investigators. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683–689.
    1. Salahudeen M, Duffull S, Nishtala P. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 2015; 15: 31.
    1. Andrew MK, Rockwood K. A five-point change in modified mini-mental state examination was clinically meaningful in community-dwelling elderly people. J Clin Epidemiol 2008; 61: 827–831.
    1. Peters R, Collerton J, Granic A, et al. Antihypertensive drug use and risk of cognitive decline in the very old: observational study - the Newcastle 85+ Study. J Hypertens 2015; 33: 2156–2164.
    1. Skoog I. Antihypertensive treatment and dementia prevention. Lancet Neurol 2008; 7: 664–665.
    1. Peters R, Schuchman M, Peters J, et al. Relationship between antihypertensive medications and cognitive impairment: part II. Review of physiology and animal studies. Curr Hypertens Rep 2016; 18: 66.
    1. Yasar S, Schuchman M, Peters J, et al. Relationship between antihypertensive medications and cognitive impairment: part I. Review of human studies and clinical trials. Curr Hypertens Rep 2016; 18: 67.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa